Sulindac in familial adenomatous polyposis: evaluation by nuclear morphometry.
OBJECTIVE
To find out if nuclear morphometry is a useful indicator of prognosis in patients with familial adenomatous polyposis (FAP) before and after treatment with sulindac.


METHODS
Open study.


METHODS
Teaching hospital, Spain.


METHODS
29 patients (17 women and 12 men) with FAP who had been treated by colectomy. There were two control groups: 17 people with healthy rectal mucosa and 10 patients with colorectal cancer.


METHODS
The 29 patients with FAP were treated with sulindac 150 mg orally twice daily for 6 months.


METHODS
Results of histological examination of biopsy specimens and nuclear morphometry.


RESULTS
Before treatment, all patients with FAP had nuclei of cells in the rectal mucosa that were intermediate in size between those in healthy mucosa (small nuclei) and those in cancer (large nuclei). After 6 months' treatment with sulindac the patients with FAP no longer had any polyps and the size of the nuclei was similar to those in healthy mucosa. Only 1 patient failed to respond, and in this patient one of the polyps subsequently became malignant.


CONCLUSIONS
Nuclear morphometry may be useful in identifying patients with FAP who are at high risk of malignant degeneration.
Fernández-López
F
F
General Surgery Department, Hospital Clínico Universitario, Santiago de Compostela, Spain. cifern@usc.es
Conde-Freire
R
R
Cadarso-Suárez
C
C
García-Iglesias
J
J
Puente-Domínguez
J L
JL
Potel-Lesquereux
J
J
D011125:Adenomatous Polyposis Coli / Q000188:drug therapy / Q000473:pathology* / Q000601:surgery; D000293:Adolescent; D000328:Adult; D000894:Anti-Inflammatory Agents, Non-Steroidal / Q000627:therapeutic use*; D015179:Colorectal Neoplasms / Q000473:pathology; D005260:Female; D006801:Humans; D007413:Intestinal Mucosa / Q000473:pathology*; D008297:Male; D012007:Rectum / Q000473:pathology*; D013467:Sulindac / Q000627:therapeutic use*
D000894:Anti-Inflammatory Agents, Non-Steroidal; D013467:Sulindac